Collaborations

Digene announces agreement with Asuragen, Inc. for cystic fibrosis screening products

Published in Gene Therapy Weekly, May 18th, 2006

Digene Corporation (DIGE) and Asuragen, Inc., a newly formed molecular diagnostic company and formerly a division of Ambion, Inc., jointly announced that the parties have entered into an exclusive, worldwide agreement for the marketing and distribution of Asuragen's cystic fibrosis (CF) screening products.

Digene has made an up-front payment to Asuragen and will make additional payments based on regulatory milestones. Additional financial details of the agreement were not disclosed.

Under the agreement, Digene will have the exclusive rights to market and distribute Asuragen's Signature CF products world-wide. In addition, Asuragen will develop, also...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2006-05-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry